Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
about
Strategically targeting MYC in cancerAdvances in sarcoma diagnostics and treatmentmTOR: An attractive therapeutic target for osteosarcoma?The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia.BRD4 inhibition suppresses cell growth, migration and invasion of salivary adenoid cystic carcinoma.The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cellsJQ1 suppresses tumor growth through downregulating LDHA in ovarian cancerThe BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.Selective and reversible suppression of intestinal stem cell differentiation by pharmacological inhibition of BET bromodomainsLoss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood SarcomaThe BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition.BET inhibitors: a novel epigenetic approach.Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.BET Proteins: An Approach to Future Therapies in Transplantation.Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the RescueDownregulation of DEPTOR inhibits the proliferation, migration, and survival of osteosarcoma through PI3K/Akt/mTOR pathway.Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.Targeting LncRNA-MALAT1 suppresses the progression of osteosarcoma by altering the expression and localization of β-catenin.The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling.Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors.Genome-wide transcriptional analysis of BRD4-regulated genes and pathways in human glioma U251 cells.The natural sweetener metabolite steviol inhibits the proliferation of human osteosarcoma U2OS cell line.CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells.Rapamycin: A promising agent to treat cancer pain?Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expressionDrug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma
P2860
Q26747745-384F898C-B8C4-48C2-9CFF-8744910CF935Q28069695-38E950C8-ECB4-4A63-AA05-AF13B51D9AF6Q28078490-CD9F9569-E492-4D6B-9DBC-E9B70909DC3DQ33714126-63CDF51C-13A9-47F5-92BC-CEC00C9B87B2Q33730555-C7AEFDB8-E579-4FC7-B368-9ADF576BEB6FQ33844624-4FAEEDFB-4B66-4339-81E9-F6018629546DQ35574955-51E93848-BE5B-4A1D-B3CC-0BD3EB23CC48Q35740107-4B4BE834-69D2-422A-AD96-01DE8AD10D8DQ36169695-C6934EA5-F72C-4680-9FA5-F07F3F9FADA2Q36559908-02712944-5095-441C-8E2C-CB60DB6CF05CQ36750689-0CB2E0A6-AE31-4B82-8C6B-FD6B2421D5AAQ36918007-67C93D06-4CEF-4837-BF0D-50D526F40F2FQ37333948-3A34BA1F-A66C-4D32-A117-7E60864F8E71Q37705651-049A7CB1-6094-4CD3-AE98-6A9417757B52Q38260084-602D6825-E9EA-49CA-9F4A-9C937433FD4DQ38609772-9D886E9E-F53E-4887-946E-6F258102F95EQ38707684-CB99AD01-7CFF-4B6B-83B7-38F0AE830F46Q38760291-054C2EF3-C1A0-49A4-A85B-52254750DCE5Q38850598-2F0E5791-31BD-40B1-B853-D93BDF9C88CFQ41080796-AA2C72C4-F562-4F4C-87ED-0B925A855F50Q41098457-71C8E373-9CFC-4E8F-A4C8-D696F3F99318Q44988870-85CB0A57-31A8-4A62-A2F6-01850ADA0533Q46924536-C04633B3-3D08-4829-AA90-E54552B857A8Q47162683-95EF4FD5-0319-40A6-8867-4286499671ADQ51213072-C09D94C6-2D41-4F18-BA31-8B71C9DF8C31Q52596812-EFF2616A-55FE-476D-AF92-DF8C7B0BC107Q52724770-D18151F0-EE5E-4669-8757-ABC420125442Q52725867-81C8E989-8ECA-4127-BDE1-458DE592CDA8Q53226917-12C94309-E23B-4B9B-9C52-23FDBA5642AFQ54192130-63BF4BE8-AE36-4544-B206-3D06B3157E97Q57068289-790C862C-C3EE-461B-8494-72F080954169Q57270689-8C2EC18D-2E81-48E9-BBA1-0611B6A70B9E
P2860
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
@ast
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
@en
type
label
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
@ast
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
@en
prefLabel
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
@ast
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
@en
P2093
P2860
P356
P1476
Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
@en
P2093
Charles Forscher
Dhong Hyun Lee
H Phillip Koeffler
Henry Yang
James E Bradner
Jonathan W Said
Ngan B Doan
P2860
P304
P356
10.1002/IJC.29269
P577
2014-10-30T00:00:00Z